Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Thomas L Holland, Sara E Cosgrove, Sarah B Doernberg, Timothy C Jenkins, Nicholas A Turner, Helen W Boucher, Oleksander Pavlov, Ivan Titov, Serhii Kosulnykov, Boyko Atanasov, Ivan Poromanski, Manana Makhviladze, Anastasia Anderzhanova, Martin E Stryjewski, Maziar Assadi Gehr, Marc Engelhardt, Kamal Hamed, Daniel Ionescu, Mark Jones, Mikael Saulay, Jennifer Smart, Harald Seifert, Vance G Fowler
BACKGROUND: Ceftobiprole is a cephalosporin that may be effective for treating complicated Staphylococcus aureus bacteremia, including methicillin-resistant S. aureus . METHODS: In this phase 3, double-blind, double-dummy, noninferiority trial, adults with complicated S. aureus bacteremia were randomly assigned in a 1:1 ratio to receive ceftobiprole at a dose of 500 mg intravenously every 6 hours for 8 days and every 8 hours thereafter, or daptomycin at a dose of 6 to 10 mg per kilogram of body weight intravenously every 24 hours plus optional aztreonam (at the discretion of the trial-site investigators)...
September 27, 2023: New England Journal of Medicine
#2
JOURNAL ARTICLE
#3
JOURNAL ARTICLE
Giuseppe Giannaccare, Massimiliano Borselli
New England Journal of Medicine, Volume 389, Issue 13, September 2023.
September 23, 2023: New England Journal of Medicine
#4
JOURNAL ARTICLE
Russ B Altman
No abstract text is available yet for this article.
September 21, 2023: New England Journal of Medicine
#5
JOURNAL ARTICLE
Cynthia A Toth
No abstract text is available yet for this article.
September 21, 2023: New England Journal of Medicine
#6
JOURNAL ARTICLE
Kekoa Taparra, Mālia Purdy, Kalani L Raphael
No abstract text is available yet for this article.
September 20, 2023: New England Journal of Medicine
#7
JOURNAL ARTICLE
Beverly Gray, Jonas J Swartz
New England Journal of Medicine, Volume 389, Issue 12, Page 1064-1066, September 2023.
September 16, 2023: New England Journal of Medicine
#8
JOURNAL ARTICLE
Steven Woloshin, Karsten Juhl Jørgensen, Shelley Hwang, H Gilbert Welch
New England Journal of Medicine, Volume 389, Issue 12, Page 1061-1064, September 2023.
September 16, 2023: New England Journal of Medicine
#9
JOURNAL ARTICLE
Alexis Kassotis, Tarun Sharma
New England Journal of Medicine, Volume 389, Issue 12, September 2023.
September 16, 2023: New England Journal of Medicine
#10
JOURNAL ARTICLE
Kamran Abbasi, Parveen Ali, Virginia Barbour, Kirsten Bibbins-Domingo, Marcel G M Olde Rikkert, Andy Haines, Ira Helfand, Richard Horton, Bob Mash, Arun Mitra, Carlos Monteiro, Elena N Naumova, Eric J Rubin, Tilman Ruff, Peush Sahni, James Tumwine, Paul Yonga, Chris Zielinski
New England Journal of Medicine, Volume 389, Issue 12, Page 1066-1067, September 2023.
September 16, 2023: New England Journal of Medicine
#11
JOURNAL ARTICLE
Salim S Abdool Karim, Francoise Barre-Sinoussi, Harold E Varmus, David Serwadda, Elizabeth Bukusi, Souleymane M'boup, Adeeba Kamarulzaman, Soumya Swaminathan, Jean W Pape
New England Journal of Medicine, Volume 389, Issue 13, Page 1159-1161, September 2023.
September 9, 2023: New England Journal of Medicine
#12
JOURNAL ARTICLE
Jane M Zhu, Hayden Rooke-Ley, Erin Fuse Brown
New England Journal of Medicine, Volume 389, Issue 11, Page 965-968, September 2023.
September 9, 2023: New England Journal of Medicine
#13
JOURNAL ARTICLE
Bishal Gyawali, Aaron S Kesselheim, Joseph S Ross
New England Journal of Medicine, Volume 389, Issue 11, Page 968-971, September 2023.
September 9, 2023: New England Journal of Medicine
#14
JOURNAL ARTICLE
Atheendar S Venkataramani
New England Journal of Medicine, Volume 389, Issue 13, Page 1157-1159, September 2023.
September 6, 2023: New England Journal of Medicine
#15
JOURNAL ARTICLE
Nishant Uppal, Steffie Woolhandler, David U Himmelstein
New England Journal of Medicine, Volume 389, Issue 10, Page 871-873, September 2023.
September 2, 2023: New England Journal of Medicine
#16
JOURNAL ARTICLE
Meng Zhang
New England Journal of Medicine, Volume 389, Issue 10, Page 874-875, September 2023.
September 2, 2023: New England Journal of Medicine
#17
JOURNAL ARTICLE
Paul G Richardson, Suzanne Trudel, Rakesh Popat, María-Victoria Mateos, Annette J Vangsted, Karthik Ramasamy, Joaquín Martinez-Lopez, Hang Quach, Robert Z Orlowski, Mario Arnao, Sagar Lonial, Chatchada Karanes, Charlotte Pawlyn, Kihyun Kim, Albert Oriol, Jesus G Berdeja, Paula Rodríguez Otero, Ignacio Casas-Avilés, Alessia Spirli, Jennifer Poon, Shaoyi Li, Jing Gong, Lilly Wong, Manisha Lamba, Daniel W Pierce, Michael Amatangelo, Teresa Peluso, Paulo Maciag, Jessica Katz, Michael Pourdehnad, Nizar J Bahlis
BACKGROUND: Despite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide. METHODS: In this phase 1-2 study, we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma. The primary objectives of phase 1 (dose-escalation cohort) were to assess safety and pharmacokinetics and to identify the dose and schedule for phase 2...
August 30, 2023: New England Journal of Medicine
#18
EDITORIAL
Jake Shortt
New England Journal of Medicine, Volume 389, Issue 11, Page 1046-1050, September 2023.
August 30, 2023: New England Journal of Medicine
#19
JOURNAL ARTICLE
Rosemary K Sokas, Emily Senay
No abstract text is available yet for this article.
August 30, 2023: New England Journal of Medicine
#20
JOURNAL ARTICLE
Barbara E Stähli, Ferdinando Varbella, Axel Linke, Bettina Schwarz, Stephan B Felix, Moritz Seiffert, Rahel Kesterke, Peter Nordbeck, Bernhard Witzenbichler, Irene M Lang, Mirjam Kessler, Christian Valina, Alban Dibra, Miklos Rohla, Marco Moccetti, Matteo Vercellino, Luise Gaede, Lorenz Bott-Flügel, Philipp Jakob, Julia Stehli, Alessandro Candreva, Christian Templin, Matthias Schindler, Manfred Wischnewsky, Greca Zanda, Giorgio Quadri, Norman Mangner, Aurel Toma, Giulia Magnani, Peter Clemmensen, Thomas F Lüscher, Thomas Münzel, P Christian Schulze, Karl-Ludwig Laugwitz, Wolfgang Rottbauer, Kurt Huber, Franz-Josef Neumann, Steffen Schneider, Franz Weidinger, Stephan Achenbach, Gert Richardt, Adnan Kastrati, Ian Ford, Willibald Maier, Frank Ruschitzka
BACKGROUND: In patients with ST-segment elevation myocardial infarction (STEMI) with multivessel coronary artery disease, the time at which complete revascularization of nonculprit lesions should be performed remains unknown. METHODS: We performed an international, open-label, randomized, noninferiority trial at 37 sites in Europe. Patients in a hemodynamically stable condition who had STEMI and multivessel coronary artery disease were randomly assigned to undergo immediate multivessel percutaneous coronary intervention (PCI; immediate group) or PCI of the culprit lesion followed by staged multivessel PCI of nonculprit lesions within 19 to 45 days after the index procedure (staged group)...
August 27, 2023: New England Journal of Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
